Glargine-300: An updated literature review on randomized controlled trials and real-world studies

Figure 1 Surface area of subcutaneous depot: Gla-100 and Gla-300. Adapted from[12].

Figure 2 Glycated haemoglobin change during the 6‐mo follow‐up period (DELIVER 2 Study)[41]. DELIVER 2, a retrospective analysis of electronic medical records from the Predictive Health Intelligence Environment database. ¹Comparison of mean reduction in Gla‐300 vs other basal insulin. ²Magnitude of HbA1c change. BI: Basal insulin; Gla-300: Insulin glargine 300 U/mL; HbA1c: Glycated haemoglobin.

Figure 3 Hypoglycaemia incidence and event rate (DELIVER 2 study)[41]. A: Percentage of patients with hypoglycemia¹ at 6-mo after basal insulin switch by insulin type; B: Adjusted mean hypoglycemia event rate² (Events/Per patient per year) during 6-mo follow-up. DELIVER 2, a retrospective analysis of electronic medical records from the Predictive Health Intelligence Environment database. ¹Adjusted for baseline hypoglycaemia incidence; ²Adjusted for baseline hypoglycaemia event rate. BI: Basal insulin; Gla-300: Insulin glargine 300 U/mL; HbA1c: Glycated haemoglobin; OR: Odds ratio; PPPY: Per patient per year.